Cytopathology

May journal-based learning exercises

Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

War on cancer pt.2: landmarks in the development of chemotherapy

The second article of two, which briefly reviews the historical developments and use of chemotherapy since 1948 to treat different cancers. 
 

April: News in numbers

A breakdown of science news this month, in numbers.

Liquid biopsy for non-small cell lung cancer

A US multi-centre study revealed that a liquid biopsy is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC).

War on cancer PT 1: the development of chemotherapy to 1950

A review of the early historical development and use of chemotherapy to treat different cancers. The phrase “war on cancer” refers to the recognition of cancer as a major cause of death and the need to act, resulting in increased funding, clinical trials and the development of more effective treatments.

3D human cell models

Medicines Discovery Catapult and the Medical Research Council Centre for Drug Safety Science at the University of Liverpool are collaborating.

My lab: cellular pathology

Consultant Cellular Pathologist Paul Cross gives a guided tour of his lab at the Queen Elizabeth Hospital, Gateshead Health NHS Foundation Trust.

A guide to Ferguson-Smith disease

What is Ferguson-Smith disease and how can it be distinguished from cutaneous squamous cell carcinoma? Chartered Scientist Jakub Jawny discusses his research.

How to… use trichrome staining for environmental surveillance of protozoan human parasites

Can trichrome staining be a cost-effective tool? Parasitology PhD student Umar Anjum and colleagues report on a pilot study.

Cutting-edge research pt.2

The IBMS has awarded five research grants this year. Here, the third successful candidate outlines the work he is undertaking.

Triple-negative breast cancer therapeutic target

Researchers have previously observed that triple-negative breast cancer (TNBC) patients with higher numbers of myeloid-derived immunosuppressor cells (MDSCs) in their bloodstream had poorer outcomes.

Top